There’s been a sharp drop in Pharmaceutical deals in the first quarter of 2017, compared with a year ago. What’s up with that?
Perrigo finally sold its royalty interest in Tysabri, a multiple sclerosis drug that it acquired as part of Elan Corporation back in 2013. Royalty Pharma, the hostile bidder for Elan back then, paid $2.2 billion for Tysabri royalties.
Johnson & Johnson swallowed hard and upped its bid for Swiss biotech Actelion, winning the deal with a $30.2 billion bid.
The final month of the fourth quarter is typically a busy one for deal makers in all industries. Last year, some health care deal makers apparently got a rest. Deal volume in December 2016 was an anemic 119 transactions, compared with 131 deals in November and 148 in December 2015. The Services sectors accounted for […]
The pharmaceutical industry has been the behemoth of healthcare M&A, usually accounting for the largest dollar amounts spent in any given year and often one of the most active in terms of number of transactions.
Overall, mergers and acquisitions slowed in Q3:16, down 11% compared with Q2:16, and 10% lower than in Q3:15. The biotechnology sector saw just the opposite phenomenon. Biotech transactions grew by 58%, to 52 deals, compared with the previous quarter’s 33 deals, and by 24% compared with the same quarter in 2015, when 42 deals were […]
Way back in February 2015, Pfizer Inc. (NYSE: PFE) agreed to pay $17 billion to acquire Hospira, Inc., a global provider of injectable drugs and infusion technologies. In early October 2016, Pfizer agreed to sell Hospira’s infusion therapy business to ICU Medical Inc. (NASDAQ: ICUI) for $1 billion in cash and stock. The company develops, manufactures and sells […]
Ever since Allergan (NYSE: AGN) completed the $40.5 billion sale of its generics business to Teva Pharmaceutical Industries (NYSE: TEVA) on August 2, the pharma giant is targeting biotech companies with a vengeance. In September alone (and we’re only talking about three weeks at this point), the company has announced four deals, totalling $1.28 billion. Year-to-date, Allergan has announced […]
Eight months into the year is a good time to take stock of the state of the healthcare M&A market. On the whole, volume and value look to be stronger than last year. The first eight months of 2016 show a combined total of 1,019 transactions, compared with 1,005 in the same period in 2015, […]
The pharmaceutical industry has largely given up on in-house research and development, saying that the R&D timeline is too costly, long and uncertain to fund with shareholders’ money. The industry has gone from bolt-on acquisitions of smaller companies with marketed products to battling it out for clinical-stage drug candidates. What’s surprised some industry observers is […]